MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcyt.2024.12.008

Медицинская библиотека · Cytotherapy · 2025

Higher risk of GVHD but better long-term survival: impact of p-ALG versus r-ATG in high-risk hematological malignancy patients following MSDT.

Yan Lingyan, Lu Linli, Wang Liwen, Yan Yuhan, Tang Yishu, Li Ying, Wang Erhua, Zhang Jian, Xiao Han, Cheng Qian, Li Xin

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Disease relapse and graft-versus-host disease (GVHD) represent significant clinical challenges for high-risk hematological malignancies (HM) patients undergoing HLA-matched sibling donor transplantation (MSDT). How to balance the effect of GVHD and Graft versus leukemia (GVL) remains unclear for high-risk HM patients receiving MSDT. Here, we conducted a retrospective study to compare the efficacy in preventing disease relapse of 2 lymphocyte-depleting antibodies (r-ATG vs p-ALG) as the GVHD prevention strategy.

METHOD: A retrospective analysis was conducted on 48 patients with high-risk HM patients who underwent MSDT at our center from January 2019 to January 2024. Among them, 22 patients were in the p-ALG group (45mg/kg), and 26 patients were in the r-ATG group (3.5-4.5mg/kg). The primary end point of this study was disease relapse.

RESULTS

We found that the p-ALG group had a higher 3-year cumulative incidence of chronic GVHD than the r-ATG group (64.4% ± 13.6% vs. 28.8% ± 9.7%, P = 0.016). There was no significant difference in total acute GVHD (aGVHD) (54.5% ± 11% vs.26.9% ± 8.9%, P = 0.81) and 3-year extensive cGVHD (20.3% ± 11.3% vs. 7.9% ± 5.5%, P = 0.27) between the 2 groups. In terms of patient prognosis, the p-ALG group showed a higher 3-year overall survival rate compared to the r-ATG group (100% vs. 75.5% ± 8.8%, P = 0.039). The 3-year disease-free survival (DFS) rate was significantly higher in the p-ALG group compared to the r-ATG group (95.5% ± 4.4% versus 61% ± 10.6%, P = 0.046). Furthermore, the p-ALG group exhibited a longer duration of disease remission after transplantation, as evidenced by a lower 3-year cumulative incidence of post-transplantation Minimal Residual Disease positivity (post-MRD+) compared to the r-ATG group (4.5% ± 4.4% versus 40.5% ± 11%, P = 0.022).

CONCLUSION

In comparison to r-ATG, the administration of low-dose p-ALG (45mg/kg) in high-risk HM patients receiving MSDT is associated with an increased incidence of GVHD but results in a more favorable survival prognosis.

Для цитирования: Yan Lingyan, Lu Linli, Wang Liwen, Yan Yuhan, Tang Yishu, Li Ying, Wang Erhua, Zhang Jian, Xiao Han, Cheng Qian, Li Xin. Higher risk of GVHD but better long-term survival: impact of p-ALG versus r-ATG in high-risk hematological malignancy patients following MSDT.. Cytotherapy. 2025. DOI: 10.1016/j.jcyt.2024.12.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.